12/05/2017

The FDA has granted full approval for Avastin® (bevacizumab) for the treatment of adults with glioblastoma

The FDA has granted full approval for Avastin^® (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as recurrent disease). Avastin was previously granted provisional approval in this setting under the FDA's accelerated approval program.

For more information, click here.